Why Cohance Lifesciences Share Price Hit Upper Circuit
The sharp rally came after Cohance Lifesciences Limited announced a major leadership change. The company has appointed Umang Vohra as Executive Chairman with effect from May 1, 2026, and as Group CEO from May 20, 2026. The announcement was made on April 27, 2026.
Mr Vohra will succeed Vivek Sharma, who is stepping down as Executive Chairman due to personal reasons. However, Mr Sharma will continue to support the company as an Advisor for the next nine months to ensure a smooth transition.
According to the company, the appointment is a deliberate and strategic decision by the Board as Cohance prepares for its next phase of transformation and growth.
Umang Vohra’s Pharma Experience
Umang Vohra brings more than three decades of experience in the pharmaceutical industry. Most recently, he served as CEO and Managing Director of Cipla Limited, where he led the company’s transformation over the last decade and helped build it into a diversified global pharmaceutical enterprise.
Commenting on his appointment, Umang Vohra said, “I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance's technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation. I am looking forward to this entrepreneurial stint and will work closely with the current management leaders to create value for customers, employees and shareholders alike.”
Leadership Transition at Cohance
Vivek Sharma said, “Over the past few years, we have built a strong foundation for Cohance, integrating businesses, strengthening the leadership team, and establishing the platform's identity as a science-led CDMO. I am proud of what the team has achieved and confident that the platform is well positioned for its next chapter. I wish Umang and the entire Cohance team every success as they take the company forward.”
Pankaj Patwari, Managing Director at Advent, said, “I am excited to welcome Umang to the Cohance family. The platform will greatly benefit from a leader like Umang, who brings an owner-manager mindset, and who can build on the business's scientific foundation, drive commercial scale, deepen customer partnerships, and develop a leading operating culture. Umang is one of the most respected leaders in the Indian pharmaceutical industry.He brings global stature, operational depth, and a track record of building and leading large-scale transformations. We are delighted to partner with him as we continue to grow the business together.”
Cohance Lifesciences Share Price Performance
As of 9:52 AM, Cohance Lifesciences share price was locked in the 20% upper circuit. The stock has gained 42.75% in the last one month. However, on a year-to-date basis, Cohance Lifesciences share price is still down by 17.46 per cent.
About Cohance Lifesciences
Cohance Lifesciences Limited is a technology-driven, integrated CDMO platform offering development and manufacturing solutions across complex APIs, performance materials, agrochemicals, ADCs, oligonucleotides and advanced chemistries to global pharmaceutical and life sciences customers.
The company has capabilities in multi-step synthesis, high-potency APIs, controlled substances, flow chemistry and continuous manufacturing. It serves leading innovator and generic pharmaceutical companies across regulated markets worldwide.
